Literature DB >> 20109753

Sustained response to mepolizumab in refractory Churg-Strauss syndrome.

Jean-Emmanuel Kahn, Catherine Grandpeix-Guyodo, Ibrahim Marroun, Emilie Catherinot, Francois Mellot, Florence Roufosse, Olivier Blétry.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20109753     DOI： 10.1016/j.jaci.2009.10.014

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  30 in total

1.  Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8.

Authors:  Ho Jeong Na; Robert G Hamilton; Amy D Klion; Bruce S Bochner
Journal:  J Immunol Methods       Date:  2012-06-06       Impact factor: 2.303

2.  Churg-strauss syndrome with eosinophilic myocarditis: a clinical pathology conference held by the division of rheumatology at hospital for special surgery.

Authors:  Alana B Levine; George Kalliolias; Mark Heaney; Yoshimi Endo; Adam Gersten; Jonathan W Weinsaft; Robert F Spiera; Anne Bass; Doruk Erkan
Journal:  HSS J       Date:  2012-06-23

3.  Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.

Authors:  Jonathan Steinfeld; Eric S Bradford; Judith Brown; Stephen Mallett; Steven W Yancey; Praveen Akuthota; Maria C Cid; Gerald J Gleich; David Jayne; Paneez Khoury; Carol A Langford; Peter A Merkel; Frank Moosig; Ulrich Specks; Peter F Weller; Michael E Wechsler
Journal:  J Allergy Clin Immunol       Date:  2018-12-19       Impact factor: 10.793

Review 4.  Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.

Authors:  Zhaleh J Amini-Vaughan; Margarita Martinez-Moczygemba; David P Huston
Journal:  Curr Allergy Asthma Rep       Date:  2012-10       Impact factor: 4.806

Review 5.  Biologic therapies targeting eosinophils: current status and future prospects.

Authors:  Fanny Legrand; Amy D Klion
Journal:  J Allergy Clin Immunol Pract       Date:  2015 Mar-Apr

Review 6.  Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.

Authors:  Eleni I Kampylafka; Harry Alexopoulos; Marinos C Dalakas; Athanasios G Tzioufas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 7.  Biological Modulators in Eosinophilic Diseases.

Authors:  Panida Sriaroon; Mark Ballow
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 8.667

Review 8.  What targeting eosinophils has taught us about their role in diseases.

Authors:  Bruce S Bochner; Gerald J Gleich
Journal:  J Allergy Clin Immunol       Date:  2010-07       Impact factor: 10.793

9.  Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.

Authors:  Michael E Wechsler; Praveen Akuthota; David Jayne; Paneez Khoury; Amy Klion; Carol A Langford; Peter A Merkel; Frank Moosig; Ulrich Specks; Maria C Cid; Raashid Luqmani; Judith Brown; Stephen Mallett; Richard Philipson; Steve W Yancey; Jonathan Steinfeld; Peter F Weller; Gerald J Gleich
Journal:  N Engl J Med       Date:  2017-05-18       Impact factor: 91.245

Review 10.  Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review.

Authors:  Loïc Raffray; Loïc Guillevin
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.